

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

**CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND
AGENT FOR THE SERVICE OF PROCESS AND NOTICES IN HONG KONG**

The Board announces that Ms. Lai Siu Kuen has been appointed as a Joint Company Secretary, Authorized Representative and Process Agent of the Company in place of Ms. Wong Yik Han with effect from 29 April 2021.

The board of directors (the “**Board**”) of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) announces that Ms. Wong Yik Han (“**Ms. Wong**”), due to change of job assignment, has resigned as a joint company secretary of the Company (the “**Joint Company Secretary**”) with effect from 29 April 2021. She has also resigned as an authorized representative of the Company pursuant to Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Authorized Representative**”) and an agent for the service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) pursuant to Rule 19A.13(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from the same date. Ms. Wong has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Ms. Lai Siu Kuen (“**Ms. Lai**”) has been appointed as a Joint Company Secretary, Authorized Representative and Process Agent all with effect from 29 April 2021 in replacement of Ms. Wong.

Ms. Lai is a Director of Corporate Services of Tricor Services Limited, an Asia’s leading business expansion specialist specializing in integrated Business, Corporate and Investor Services. Ms. Lai has over 20 years of experience in the corporate secretarial field. She has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Lai is a Chartered Secretary and a Fellow of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute (formerly The Institute of Chartered Secretaries and Administrators).

Ms. Lai and Ms. Chen Yingge (“**Ms. Chen**”) will act as the Joint Company Secretaries of the Company.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to waiver granted to the Company by the Stock Exchange from strict compliance with the requirements of Rule 3.28 and Rule 8.17 of the Listing Rules in respect of the acting by Ms. Chen as a Joint Company Secretary for a three-year period from 24 December 2018 to 23 December 2021 (the “**Original Waiver**”) and the announcement of the Company dated 14 January 2020 (the “**Announcement**”) regarding the change of joint company secretary on 14 January 2020 and the waiver granted to the Company by the Stock Exchange from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) for the period from 14 January 2020 to 23 December 2021 (the “**Waiver Period**”) on certain conditions. One of the conditions is that Ms. Chen would be assisted by Ms. Wong during the Waiver Period and the Waiver would be revoked immediately if and when Ms. Wong ceased to provide assistance to Ms. Chen. For further details of the Original Waiver and the Waiver, please refer to the prospectus of the Company dated 11 December 2018 and the Announcement respectively.

In light of Ms. Wong’s resignation, the Company has applied for, and the Stock Exchange has granted, a new waiver (the “**New Waiver**”) from strict compliance with the relevant requirements under Rule 3.28 and Rule 8.17 of the Listing Rules for the remaining Waiver Period (i.e. 29 April 2021 to 23 December 2021), on the conditions that:

- (i) Ms. Chen will be assisted by Ms. Lai during the remaining Waiver Period;
- (ii) at the end of the remaining Waiver Period, the Company will re-assess Ms. Chen’s qualifications and experience and shall notify the Stock Exchange to re-visit the situation. The Company is expected to demonstrate at the end of the remaining Waiver Period that Ms. Chen, having had the benefit of Ms. Lai’s assistance, will satisfy the requirements under Rule 3.28 of the Listing Rules, such that a further waiver will not be necessary; and
- (iii) details of the New Waiver will be disclosed in this announcement.

The New Waiver will be revoked if and when Ms. Lai ceases to be a Joint Company Secretary.

The Board would like to express its gratitude to Ms. Wong for her valuable efforts and contributions to the Company and take the opportunity to express its warm welcome to Ms. Lai on her new appointment.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 29 April 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing and Dr. Yao Sheng as executive Directors; Dr. Wu Hai, Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.

* For identification purpose only